시장보고서
상품코드
1272054

세계의 인간화 마우스 및 래트 모델 시장 : 유형별(유전자, 세포 기반(CD34, PBMC, BLT), 용도별(신경과학, 종양학, 독성학, 면역학 및 감염학, 조혈), 최종사용자 및 지역별 예측(-2027년)

Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Oncology, Toxicology, Immunology & Infectious diseases, Hematopoiesis), End Users, and Region - Global Forecast to 2027

발행일: | 리서치사: MarketsandMarkets | 페이지 정보: 영문 180 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 인간화 마우스 및 래트 모델 시장 규모는 2022년 2억 3,700만 달러에서 2027년까지 3억 3,800만 달러에 달할 것으로 예상되며, 2022년부터 2027년까지 예측 기간 동안 연평균 7.4% 성장할 것으로 예상됩니다. 현재 기능적인 인간 세포, 유전자 및 조직이 이식된 면역 결핍 마우스는 인간 질병에 대한 전임상 연구의 중요한 도구로 부상하고 있습니다. 유전적, 생물학적, 행동학적 특성이 인간과 유사하기 때문에 의학적인 검사는 인간화 모델에서 이루어집니다. 또한, 인간의 일부 병적 상태는 인간화 모델에서 재현할 수 있기 때문에 시장 성장을 가속하고 있습니다. 또한, 인간화 마우스 및 래트 모델 시장의 성장에는 개인 맞춤형 의료에 대한 수요 증가, 정부 및 민간 기업의 투자 및 보조금 지원 확대, 제약 및 생명공학 기업의 연구개발 활동 증가 등이 있습니다.

인간화 래트 모델 시장은 유형별 부문에서 두 번째로 큰 점유율을 차지할 것으로 예상됩니다.

유형별로 인간화 마우스 및 래트 모델 시장은 인간화 마우스 모델과 인간화 래트 모델로 분류되며, 2021년에는 인간화 래트 모델 시장이 두 번째로 큰 점유율을 차지할 것으로 예상됩니다. 쥐의 간 대사(간 효소의 수와 유형 등)는 인간과 유사합니다. 또한 쥐를 외과 적으로 개조하고 샘플을 채취하는 것이 더 쉽습니다. 래트 모델의 다른 장점으로는 좋은 흡수성, 취급 용이성, 더 강한 정맥 투여를 견딜 수 있는 능력, 더 큰 조직 샘플 등을 들 수 있습니다. 마우스 모델에 비해 래트 모델의 이러한 장점은 인간화 래트 모델의 개발을 촉진하고 있습니다.

인간화 마우스-래트 모델 시장의 용도별로는 종양 부문이 가장 높은 점유율을 차지하고 있습니다.

인간화 마우스 및 래트 모델 시장은 용도별로 종양학, 면역학 및 감염학, 신경과학, 조혈학, 독성학, 기타로 구분됩니다. 인간화 마우스 모델은 유전자 기능 검증, 신규 암 유전자 및 종양 바이오마커 발굴, 종양 형성의 기초가 되는 분자 및 세포 기전 이해, 새로운 치료 전략 검증을 위한 우수한 임상 모델을 제공하기 때문에 암 생물학 이해에 크게 기여하고 있으며, 2021년에 종양학 용도가 가장 높은 시장 점유율을 차지하고 있습니다.

유럽은 인간화 마우스 및 래트 모델 시장에서 두 번째로 큰 지역입니다.

인간화 마우스 및 래트 모델 시장은 북미, 유럽, 아시아태평양, 라틴아메리카(LATAM), 중동 및 아프리카(MEA)로 구분됩니다. 북미에 이어 유럽이 높은 시장점유율을 보이는 이유는 의약품 연구개발비용 증가와 제약 및 바이오테크놀로지의 성장이 주요 요인으로 작용하고 있습니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 프리미엄 인사이트

제5장 시장 개요

  • 서론
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
    • 과제
  • 규제 분석
  • 가격 분석
  • 기술 분석
  • 밸류체인 분석
  • 인간화 마우스 및 래트 모델 시장 생태계 분석
  • Porter의 Five Forces 분석
  • 특허 분석

제6장 인간화 마우스 및 래트 모델 시장 : 유형별

  • 서론
  • 인간화 마우스 모델
    • 유전자
    • 세포 기반
  • 인간화 래트 모델

제7장 인간화 마우스 및 래트 모델 시장 : 용도별

  • 서론
  • 종양학
  • 면역학 및 감염증
  • 신경과학
  • 조혈
  • 독성학
  • 기타

제8장 인간화 마우스 및 래트 모델 시장 : 최종사용자별

  • 서론
  • 제약 기업 및 바이오테크놀러지 기업
  • 임상시험 수탁기관
  • 학술기관 및 연구기관

제9장 인간화 마우스 및 래트 모델 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 일본
    • 인도
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카

제10장 경쟁 구도

  • 개요
  • 주요 기업 전략/유력 기업
  • 시장 점유율 분석
  • 기업 평가 매트릭스
  • 기업 평가 매트릭스 : 스타트업/중소기업
  • 기업 실적 분석
  • 경쟁 시나리오

제11장 기업 개요

  • 주요 기업
    • CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • THE JACKSON LABORATORY
    • TACONIC BIOSCIENCES, INC.
    • CROWN BIOSCIENCE
    • CHAMPIONS ONCOLOGY, INC.
    • INOTIV
    • HERA BIOLABS
    • GENOWAY
    • BEIJING VITALSTAR BIOTECHNOLOGY CO. LTD.
    • INGENIOUS TARGETING LABORATORY
    • AXENIS
    • TRANS GENIC
    • HARBOUR ANTIBODIES(A SUBSIDIARY OF HARBOUR BIOMED)
    • ONCODESIGN
    • PHARMATEST SERVICES
  • 기타 기업
    • OZGENE PTY LTD.
    • TRANSCURE BIOSERVICES
    • CYAGEN BIOSCIENCES
    • GVK BIO
    • BIOCYTOGEN

제12장 부록

LSH 23.05.24

The global humanized mouse and rat model market is projected to reach USD 338 million by 2027 from USD 237 million in 2022, at a CAGR of 7.4% during the forecast period of 2022 to 2027. Currently, immunodeficient mice engrafted with functional human cells, genes, and tissues have emerged as an important tool for the preclinical study of human diseases. Medical testing is done on humanized models as their genetic, biological, and behavioural characteristics resemble those of humans. Also, several medical conditions of humans can be replicated in humanized models and this is promoting market growth. Along with this growth in the humanized mouse and rat model market can be attributed to increased demand for personalized medicine, growing support through investments and grants from the government and private sector, and growth in the number of R&D activities carried out by pharmaceutical and biotechnology companies is driving market growth.

Humanized Rat Model Market is expected to account for the second-largest share for by type segment.

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2021, humanized rat model market accounted for the second largest share. The liver metabolism of rats (in terms of the number and type of liver enzymes) is similar to humans. It is also easy to surgically modify rats and collect samples. The other advantages of rat models include favourable absorption, ease of handling, ability to sustain more intense intravenous dosing, and larger tissue sample. These advantages of rat models over mouse models are encouraging the development of humanized rat models.

The Oncology segment accounted for the highest market share of the application segment in the humanized mouse and rat model market

Based on application, the humanized mouse and rat model market is segmented into oncology, immunology and infectious diseases, neuroscience, haematopoiesis, toxicology, and other applications. In 2021 Oncology application had the highest market share as humanized mouse models have significantly contributed to the understanding of cancer biology, as they are useful in validating gene functions, identifying novel cancer genes & tumor biomarkers, understanding the molecular and cellular mechanisms underlying in tumor initiation, and providing better clinical models to test novel therapeutic strategies.

Europe is the second largest region in the humanized mouse and rat model market

The humanized mouse and rat model market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). After North America, In Europe, the growing pharmaceutical R&D expenditure and growth in the pharmaceutical and biotechnology are major driver for high market share.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 80% and Demand Side 20%
  • By Designation: Managers- 55%, CXOs and Director level - 20%, and Executives - 25%
  • By Region: North America -45%, Europe -30%, Asia-Pacific -20%, Latin America -3%, and Middle East and Africa - 2%

Prominent Players of the humanized mouse and rat model market are Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), Envigo (US).

Research Coverage:

This report provides a detailed picture of the humanized mouse and rat model market. It aims at estimating the size and future growth potential of the market across different segments such as the type, application, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall humanized mouse and rat model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing research activities using humanized models, Rising demand for personalized medicine, Continuous support and initiatives from government and private sectors

for cancer research, and Growing R&D activities in pharmaceutical and biotechnology sectors), restraint (High cost of custom humanized models, Laws and regulations for ethical use of animal models in research), opportunities (Rising demand for humanized PDX models, Emergence of CRISPR as a powerful tool in biomedical research, Rising demand for humanized rat models), challenges (Alternatives for animal testing, Limitations of humanized mouse models) are influencing the growth of humanized mouse and rat model market.

  • Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the humanized mouse and rat model market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the humanized mouse and rat model market across varied regions.
  • Market Diversification: Exhaustive information about new product, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Envigo (US), among others in the humanized mouse and rat model market. The report also helps stakeholders understand the pulse of humanized mouse and rat model market and provides them information on key market drivers, restraints, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH APPROACH
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primary sources
    • FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
      • 2.1.2.2 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS
    • FIGURE 3 CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • FIGURE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: FINAL CAGR PROJECTIONS
    • FIGURE 5 HUMANIZED MOUSE AND RAT MODEL MARKET: SEGMENTAL ASSESSMENT
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 6 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET RANKING ANALYSIS
  • 2.5 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY

    • FIGURE 7 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 REGIONAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET

4 PREMIUM INSIGHTS

  • 4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
    • FIGURE 11 GROWING RESEARCH ACTIVITIES USING HUMANIZED MODELS TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY (2021)
    • FIGURE 12 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES SEGMENT DOMINATED ASIA PACIFIC MARKET IN 2021
  • 4.3 GEOGRAPHICAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET
    • FIGURE 13 INDIA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027
  • 4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION
    • FIGURE 14 NORTH AMERICA TO DOMINATE MARKET IN 2027
  • 4.5 HUMANIZED MOUSE AND RAT MODEL MARKET: DEVELOPED VS. DEVELOPING MARKETS
    • FIGURE 15 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 16 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing research activities using humanized models
      • 5.2.1.2 Rising demand for personalized medicine
      • 5.2.1.3 Continuous support and initiatives from government and private sectors for cancer research
      • 5.2.1.4 Growing R&D activities in pharmaceutical and biotechnology sectors
    • TABLE 1 NUMBER OF DRUGS IN DEVELOPMENT, BY DISEASE AREA (2020)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of custom humanized models
      • 5.2.2.2 Laws and regulations for ethical use of animal models in research
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for humanized PDX models
      • 5.2.3.2 Emergence of CRISPR as a powerful tool in biomedical research
      • 5.2.3.3 Rising demand for humanized rat models
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Alternatives for animal testing
      • 5.2.4.2 Limitations of humanized mouse models
  • 5.3 REGULATORY ANALYSIS
    • 5.3.1 NORTH AMERICA
    • 5.3.2 EUROPE
    • 5.3.3 ASIA PACIFIC
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
    • 5.3.4 LATIN AMERICA
    • 5.3.5 MIDDLE EAST & AFRICA
  • 5.4 PRICING ANALYSIS
    • TABLE 2 PRICE OF HUMANIZED MOUSE MODELS (2022)
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 17 CREATION OF HUMANIZED MODELS-MAXIMUM VALUE IS ADDED DURING IMPLANTATION OF GRAFT/TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
  • 5.7 ECOSYSTEM ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET
    • FIGURE 18 ECOSYSTEM ANALYSIS OF HUMANIZED MOUSE AND RAT MODEL MARKET
    • TABLE 3 SUPPLY CHAIN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 4 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 PATENT ANALYSIS
    • FIGURE 19 PATENT APPLICATIONS FOR HUMANIZED MOUSE MODEL MARKET, JANUARY 2013 -SEPTEMBER 2022

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 5 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
  • 6.2 HUMANIZED MOUSE MODELS
    • TABLE 6 HUMANIZED MOUSE MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 7 HUMANIZED MOUSE MODEL MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.1 GENETIC HUMANIZED MOUSE MODELS
      • 6.2.1.1 Genetic humanized mouse models segment to account for larger market share
    • TABLE 8 GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • 6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
    • TABLE 9 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 10 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.2.2.1 CD34 humanized mouse models
        • 6.2.2.1.1 Increasing demand for stem cell therapy to drive market growth
    • TABLE 11 CD34 HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.2.2.2 PBMC humanized mouse models
        • 6.2.2.2.1 Growing prevalence of infectious diseases to drive demand
    • TABLE 12 PBMC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
      • 6.2.2.3 BLT humanized mouse models
        • 6.2.2.3.1 Increasing HIV cases to drive demand
    • TABLE 13 BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
  • 6.3 HUMANIZED RAT MODELS
    • 6.3.1 LACK OF GERMLINE-COMPETENT RAT EMBRYONIC STEM CELL LINES AFFECTED ADOPTION OVER LAST TWO DECADES
    • TABLE 14 HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 15 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 7.2 ONCOLOGY
    • 7.2.1 INCREASING APPLICATIONS OF MOUSE MODELS IN CANCER STUDIES TO DRIVE GROWTH
    • TABLE 16 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.3 IMMUNOLOGY AND INFECTIOUS DISEASES
    • 7.3.1 DEVELOPMENT OF ADVANCED MODELS FOR HUMAN IMMUNOLOGY STUDIES TO BOOST GROWTH
    • TABLE 17 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.4 NEUROSCIENCE
    • 7.4.1 INCREASING FOCUS ON HUMANIZED MOUSE MODEL DEVELOPMENT FOR CNS DISORDERS TO PROPEL GROWTH
    • TABLE 18 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.5 HEMATOPOIESIS
    • 7.5.1 GROWING DEMAND FOR STEM CELL THERAPY TO PROPEL GROWTH
    • TABLE 19 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.6 TOXICOLOGY
    • 7.6.1 RISING NUMBER OF CLINICAL STUDIES TO DRIVE DEMAND
    • TABLE 20 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)
  • 7.7 OTHER APPLICATIONS
    • TABLE 21 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2020-2027 (USD MILLION)

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

  • 8.1 INTRODUCTION
    • TABLE 22 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 8.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    • 8.2.1 INCREASING R&D ON DRUG DEVELOPMENT TO DRIVE GROWTH
    • TABLE 23 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.3 CONTRACT RESEARCH ORGANIZATIONS
    • 8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES TO DRIVE GROWTH
    • TABLE 24 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)
  • 8.4 ACADEMIC AND RESEARCH INSTITUTIONS
    • 8.4.1 INCREASING LIFE SCIENCE R&D EXPENDITURE TO DRIVE GROWTH
    • TABLE 25 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2020-2027 (USD MILLION)

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION

  • 9.1 INTRODUCTION
    • TABLE 26 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 9.2 NORTH AMERICA
    • FIGURE 20 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET SNAPSHOT
    • TABLE 27 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 28 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 29 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 30 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 31 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 32 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.1 US
      • 9.2.1.1 US to dominate North American market
    • TABLE 33 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 34 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 35 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 36 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 37 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.2.2 CANADA
      • 9.2.2.1 Government initiatives to drive market growth
    • TABLE 38 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 39 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 40 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 41 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 42 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.3 EUROPE
    • TABLE 43 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 44 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 45 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 46 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 47 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 48 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.1 GERMANY
      • 9.3.1.1 Germany to account for largest share in European market
    • TABLE 49 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 50 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 51 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 52 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 53 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.2 UK
      • 9.3.2.1 Increasing cancer research to drive growth
    • TABLE 54 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 55 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 56 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 57 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 58 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.3 FRANCE
      • 9.3.3.1 Increasing government funding for research and investments in genomics to drive growth
    • TABLE 59 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 60 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 61 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 62 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 63 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.4 ITALY
      • 9.3.4.1 Increasing pharmaceutical production in Italy to drive growth
    • TABLE 64 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 65 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 66 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 68 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.5 SPAIN
      • 9.3.5.1 Rising R&D expenditure to boost growth
    • TABLE 69 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 70 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 71 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 72 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 73 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.3.6 REST OF EUROPE
    • TABLE 74 ROE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 75 ROE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 ROE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 77 ROE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 78 ROE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.4 ASIA PACIFIC
    • FIGURE 21 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET SNAPSHOT
    • TABLE 79 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 81 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 82 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 83 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.1 CHINA
      • 9.4.1.1 China to dominate Asia Pacific market
    • TABLE 85 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 86 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 87 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 88 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 89 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.2 JAPAN
      • 9.4.2.1 Growing research collaborations to drive market growth in Japan
    • TABLE 90 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 91 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 92 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 93 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 94 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.3 INDIA
      • 9.4.3.1 Growing biotech industry in India to drive market growth
    • TABLE 95 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 96 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 97 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 98 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 99 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.4 SOUTH KOREA
      • 9.4.4.1 Growing efforts by government to drive market growth
    • TABLE 100 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 101 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 102 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 103 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 104 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 9.4.5 REST OF ASIA PACIFIC
    • TABLE 105 ROAPAC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 106 ROAPAC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 107 ROAPAC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 108 ROAPAC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 109 ROAPAC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.5 LATIN AMERICA
    • 9.5.1 INCREASING PHARMACEUTICAL R&D EXPENDITURE TO DRIVE MARKET GROWTH
    • TABLE 110 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 111 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 112 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 113 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 114 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 UAE HAS EMERGED AS KEY MARKET IN MEA REGION
    • TABLE 115 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 116 MIDDLE EAST & AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 117 MIDDLE EAST & AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 118 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 119 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2020-2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • FIGURE 22 KEY DEVELOPMENTS IN HUMANIZED MOUSE AND RAT MODEL MARKET, 2019-2022
  • 10.3 MARKET SHARE ANALYSIS
    • FIGURE 23 HUMANIZED MOUSE AND RAT MODEL MARKET SHARE, BY KEY PLAYER, 2021
    • TABLE 120 HUMANIZED MOUSE AND RAT MODEL MARKET: DEGREE OF COMPETITION
  • 10.4 COMPANY EVALUATION MATRIX
    • 10.4.1 STARS
    • 10.4.2 EMERGING LEADERS
    • 10.4.3 PERVASIVE PLAYERS
    • 10.4.4 PARTICIPANTS
    • FIGURE 24 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX, 2021
  • 10.5 COMPANY EVALUATION MATRIX: START-UPS/SMES
    • 10.5.1 PROGRESSIVE COMPANIES
    • 10.5.2 STARTING BLOCKS
    • 10.5.3 RESPONSIVE COMPANIES
    • 10.5.4 DYNAMIC COMPANIES
    • FIGURE 25 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2021
  • 10.6 FOOTPRINT ANALYSIS OF COMPANIES
    • 10.6.1 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 121 PRODUCT FOOTPRINT OF COMPANIES: HUMANIZED MOUSE AND RAT MODEL MARKET (2021)
    • 10.6.2 END-USER FOOTPRINT OF COMPANIES
    • TABLE 122 END-USER FOOTPRINT OF COMPANIES: HUMANIZED MOUSE AND RAT MODEL MARKET (2021)
    • 10.6.3 REGIONAL FOOTPRINT OF COMPANIES
    • TABLE 123 REGIONAL FOOTPRINT OF COMPANIES: HUMANIZED MOUSE AND RAT MODEL MARKET (2021)
  • 10.7 COMPETITIVE SCENARIO
    • TABLE 124 PRODUCT LAUNCHES
    • TABLE 125 DEALS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
  • (Business Overview, Products offered, Recent Developments, MnM View)**
    • 11.1.1 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
    • TABLE 126 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW
    • FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021)
    • 11.1.2 THE JACKSON LABORATORY
    • TABLE 127 THE JACKSON LABORATORY: BUSINESS OVERVIEW
    • FIGURE 27 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2021)
    • 11.1.3 TACONIC BIOSCIENCES, INC.
    • TABLE 128 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW
    • 11.1.4 CROWN BIOSCIENCE
    • TABLE 129 CROWN BIOSCIENCE: BUSINESS OVERVIEW
    • 11.1.5 CHAMPIONS ONCOLOGY, INC.
    • TABLE 130 CHAMPIONS ONCOLOGY: BUSINESS OVERVIEW
    • FIGURE 28 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2022)
    • 11.1.6 INOTIV
    • TABLE 131 INOTIV: BUSINESS OVERVIEW
    • FIGURE 29 INOTIV: COMPANY SNAPSHOT
    • 11.1.7 HERA BIOLABS
    • TABLE 132 HERA BIOLABS: BUSINESS OVERVIEW
    • 11.1.8 GENOWAY
    • TABLE 133 GENOWAY: BUSINESS OVERVIEW
    • 11.1.9 BEIJING VITALSTAR BIOTECHNOLOGY CO. LTD.
    • TABLE 134 VITALSTAR BIOTECHNOLOGY: BUSINESS OVERVIEW
    • 11.1.10 INGENIOUS TARGETING LABORATORY
    • TABLE 135 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW
    • 11.1.11 AXENIS
    • TABLE 136 AXENIS: BUSINESS OVERVIEW
    • 11.1.12 TRANS GENIC
    • TABLE 137 TRANS GENIC: BUSINESS OVERVIEW
    • 11.1.13 HARBOUR ANTIBODIES (A SUBSIDIARY OF HARBOUR BIOMED)
    • TABLE 138 HARBOUR ANTIBODIES: BUSINESS OVERVIEW
    • 11.1.14 ONCODESIGN
    • TABLE 139 ONCODESIGN: BUSINESS OVERVIEW
    • 11.1.15 PHARMATEST SERVICES
    • TABLE 140 PHARMATEST SERVICES: BUSINESS OVERVIEW
  • *Details on Business Overview, Products offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
  • 11.2 OTHER PLAYERS
    • 11.2.1 OZGENE PTY LTD.
    • 11.2.2 TRANSCURE BIOSERVICES
    • 11.2.3 CYAGEN BIOSCIENCES
    • 11.2.4 GVK BIO
    • 11.2.5 BIOCYTOGEN

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 CUSTOMIZATION OPTIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제